Financings Roundup
ThromboGenics Extends Runway with $103.2M Raise
Ten days after inking a potential $494 million deal with eye care specialist Alcon Inc. for the ex-U.S. rights to vitreous macular adhesion (VMA) candidate ocriplasmin, ThromboGenics NV raised €77.8 million (US$103.2 million) in a private placement of 3,244,677 new shares with domestic and international investors.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.